NCT00725283View on ClinicalTrials.gov

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 1, 2008

Primary Completion Date

June 22, 2016

Study Completion Date

June 22, 2016

Conditions
Leukaemia, Myelocytic, Acute
Interventions
BIOLOGICAL

GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)

Intramuscular administration

Trial Locations (10)

10032

GSK Investigational Site, New York

14263

GSK Investigational Site, Buffalo

21201

GSK Investigational Site, Baltimore

33612

GSK Investigational Site, Tampa

37232

GSK Investigational Site, Nashville

38043

GSK Investigational Site, Grenoble

78229

GSK Investigational Site, San Antonio

01655

GSK Investigational Site, Worcester

27157-1009

GSK Investigational Site, Winston-Salem

98109-1023

GSK Investigational Site, Seattle

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY